Bio-Solutions Corp.
OTC Bulletin Board : BISU

Bio-Solutions Corp.

September 06, 2011 13:15 ET

Bio Solutions Corp./Type2 Defense: Product Update

MONTREAL, CANADA--(Marketwire - Sept. 6, 2011) - (OTCBB:BISU)(PINK SHEETS:BISU) - Bio Tech marketing company Bio Solutions Corp. is pleased to provide a Type2 Defense product update. "With our recent LOI to acquire all rights of Type2 Defense dietary supplement, this gives us the platform we are looking for to enter the high growth Diabetic industry. We have now turned our attention to this disease in the USA, which continues to grow at an alarming rate every year. Diabetes is attributed to some of the lead causes of deaths in America, prevention and maintenance is key." stated Gilles Chaumillon President and CEO.

Just to clarify, Type2 Defense is a proprietary blend of clinically tested and approved ingredients that promote healthy glucose levels. We at Bio-Solutions Corp, are not conducting clinical trials of any kind. The active ingredients in Type2 Defense have all been cleared by their various respective regulatory agencies, for human consumption.

Type2 Defense proprietary blend was developed by Dr. Chandrasekhar Mallangi. Dr. Mallangi was previously the head of Nestle, Nutritional product development for 25 years.

Type2 Defense is a dietary supplement formulated to support healthy glucose for type 2 diabetics and pre-diabetics. Type2 Defense high anti-oxidant proprietary blend of cinnamon and blueberry extracts, have been clinically proven supplements that assists in maintaining healthy blood glucose levels. Type2 Defense powder blend is a flavorful supplement within a convenient powder delivery system. When mixed with water T2 becomes an effective vehicle to promote healthy glucose levels.

Type2 Defense, will be packaged with 30 pouches per box, it is the first powder supplement delivery system of its kind. Type2 Defense was created to become the largest direct response delivery system of glucose control supplements. "Customers will sign up for a 12 month membership program; we will begin taking membership subscriptions after completion of the Type2 Defense shopping cart page." stated new Executive VP Bill Gallagher.

Mr. Gallagher recently joined Bio-Solutions Corp. along with the likes of talent such as Dr. Mallangi, Mr. Gallagher comes with his 40 plus years experience in marketing glucose control beverages, working with the major wholesale retail clubs, larger everyday online merchants and working with the top home delivery merchandisers in the USA.

According to the CDC's 2011 diabetes Fact Sheet. (

There is an estimated 100 Plus Million Americans at risk of diabetes in the following order:

Total prevalence of diabetes

Total: 25.8 million children and adults in the United States—8.3% of the population—have diabetes.
Diagnosed: 18.8 million people
Undiagnosed: 7.0 million people
Prediabetes: 79 million people*
New Cases: 1.9 million new cases of diabetes are diagnosed in people aged 20 years and older in 2010.
* In contrast to the 2007 National Diabetes Fact Sheet, which used fasting glucose data to estimate undiagnosed diabetes and prediabetes, the 2011 National Diabetes Fact Sheet uses both fasting glucose and A1C levels to derive estimates for undiagnosed diabetes and prediabetes. These tests were chosen because they are most frequently used in clinical practice.

"Given the two types of Diabetes (Type 1 and Type 2), our product will predominantly cater to obviously Types 2 patients, which are 90-95%, of all diabetics. Our supplement will aid to combat in the major against complications of Diabetes which include:

1) Heart disease and stroke

2) High blood pressure

  • In 2005-2008, of adults aged 20 years or older with self-reported diabetes, 67% had blood pressure greater than or equal to 140/90 mmHg or used prescription medications for hypertension.

3) Kidney disease

  • Diabetes is the leading cause of kidney failure, accounting for 44% of new cases in 2008.
  • In 2008, 48,374 people with diabetes began treatment for end-stage kidney disease in the United States.
  • In 2008, a total of 202,290 people with end-stage kidney disease due to diabetes were living on chronic dialysis or with a kidney transplant in the United States.

4) Nervous system disease (Neuropathy)

  • About 60% to 70% of people with diabetes have mild to severe forms of nervous system damage.

According to (1/27/11 Big Pharma Article): "In 2009, the U.S. diabetes market grew 17% from 2008, reaching $14.9 billion, according to data from health care information company IMS Health. Worldwide, the market generated sales of over $25 Billion, according to independent business information provider Vision again. By 2019, Morningstar projects the worldwide diabetes market, excluding insulin, will grow to over $55 billion... According to IMS Health, the top-selling diabetes drugs in the U.S. now are Takeda's oral drug Actos, with nearly $1.8 billion in sales in the first half on 2010; Sanofi-Aventis's (SNY) Lantus products, with nearly $1.5 billion in sales, and Merck's (MRK) Januvia, with $854 million in sales. The total diabetes market in the first half of 2010 was $8.7 billion, nearly as much as full-year 2005's market of $9.3 billion.

Rounding out the top five diabetes drugs in the U.S. are Novo-Nordisk's (NVO) Novolog and Eli-Lilly's (LLY) Humalog, both of which are analog insulin drugs. Other players include Lilly and Amylin's (AMLN) Byetta, which had Q4 2010 sales of $174.6 million, and Novo-Nordisk's Victoza, which had sales of roughly $127 million in Q3. Both are antidiabetes hormone analog drugs."

For more information on Bio-Solutions Corp. and its products, please visit the company's website at

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Bio-Solutions actual results to differ materially from those in the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.

Contact Information

  • Contact Investor & Public Relations
    Harald van der Kam
    484-971-5844 (FAX)